Table 2.
Clinical characteristics of participants in MIGen, UK Biobank and TSCA.
| MIGen | UK Biobank (Sequencing and Genotyping) |
TSCA | |
|---|---|---|---|
| N = 48,576 | N = 336,357 | N = 1,714 | |
| Age, years (SD) | 54 (10) | 57 (8) | 57.2 (13) |
| Male gender, n (%) | 41,203 (71) | 156,112 (46) | 1,140 (67) |
| BMI (SD), kg/m2 | 27 (5) | 27 (5) | 29 (6) |
| Current smoker, n (%) | 18,173 (33) | 25,802 (8) | 639 (37) |
| Medical history | |||
| Coronary artery disease, n (%) | 16,106 (33) | 12,073 (3) | 1,184 (69) |
| Hypertension, n (%) | 16,839 (35) | 153,535 (46) | 798 (47) |
| Type 2 diabetes, n (%) | 11,245 (22) | 15,770 (5) | 277 (16) |
| Lipid profile | |||
| Total cholesterol, mg/dL (SD) | 178 (60) | 222 (41) | 182 (51) |
| LDL cholesterol, mg/dL† (SD) | 109 (45) | 138 (34) | 108 (41) |
| HDL cholesterol, mg/dL (SD) | 36 (14) | 56 (15) | 43 (7) |
| Triglycerides, mg/dL (SD) | 154 (127) | 155 (90) | 135 (82) |
Abbreviations: MIGen, Myocardial Infarction Genetics consortium; SD, standard deviation; TSCA, TruSeq Custom Amplicon target resequencing studies.